Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRVO bevacizumab versus ranibizumab trial in retinal vein occlusion-related macular edema
NL-OMON23545Not yet recruiting
- Sponsor
- Academic Medical Center Department of Ophthalmology
- Start
- Apr 2012
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in Vein occlusion (RVO) and macular edema comparing Bevacizumab with Ranibizumab (2 arms). Primary endpoint: Change in best-corrected visual acuity from baseline to month 6. Planned start Apr 2012; status: not yet recruiting.
02
Drugs
bevacizumabranibizumab
03
Conditions
Vein occlusion (RVO)macular edema
Beyond the preview
Go deeper on NL-OMON23545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23545.